Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis

References

• Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291–297.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Bakris GL. Kidney disease and hypertension. In: Lip G, Hall J, editors. Comprehensive hypertension. London: Elsevier; 2007, pp. 607-619.
   Google Scholar
• Sarafidis PA, Persu A, Agarwal R, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the kidney working group of the European Society of Hypertension (ESH). J Hypertens. 2017;35:657–676.
   PubMed Web of Science ®Google Scholar
• Zucchelli P, Santoro A, Zuccala A. Genesis and control of hypertension in hemodialysis patients. Semin Nephrol. 1988;8:163–168.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Alborzi P, Satyan S, et al. Dry-weight reduction in hypertensive patients (DRIP). A randomized, controlled trial. Hypertension. 2009;53:500–507.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Weir MR. Dry-weight: a concept revisited in an effort to avoid medication-directed approaches for blood pressure control in hemodialysis patients: Figure 1. Clin J Am Soc Nephrol. 2010;5:1255–1260.
   PubMed Web of Science ®Google Scholar
• Redon J, Martinez F, Cheung AK. Special considerations for antihypertensive agents in dialysis patients. Blood Purif. 2010;29:93–98.
   PubMed Web of Science ®Google Scholar
• Levin NW, Kotanko P, Eckardt KU, et al. Blood pressure in chronic kidney disease stage 5D-report from a kidney disease: improving global outcomes controversies conference. Kidney Int. 2010;77:273–284.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Flynn J, Pogue V, et al. Assessment and management of hypertension in patients on dialysis. J Am Soc Nephrol. 2014;25:1630–1646.
   PubMed Web of Science ®Google Scholar
• K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45(Suppl 3):S1–153.
   Google Scholar
• Hirakata H, Nitta K, Inaba M, et al. Japanese Society for dialysis therapy guidelines for management of cardiovascular diseases in patients on chronic hemodialysis. Ther Aphel Dial. 2012;16:387–435.
   PubMedGoogle Scholar
• Parati G, Ochoa JE, Bilo G, et al. Hypertension in chronic kidney disease Part 1: out-of-office blood pressure monitoring: methods, thresholds, and patterns. Hypertension. 2016;67:1093–1101.
   PubMed Web of Science ®Google Scholar
• Parati G, Ochoa JE, Bilo G, et al. Hypertension in chronic kidney disease Part 2: role of ambulatory and home blood pressure monitoring for assessing alterations in blood pressure variability and blood pressure profiles. Hypertension. 2016;67:1102–1110.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Pro: ambulatory blood pressure should be used in all patients on hemodialysis. Nephrol Dial Transplant. 2015;30:1432–1437.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Rumjon A, Macdougall IC. Ambulatory blood pressure monitoring: an invaluable tool comes of age for patients with chronic kidney disease? Am J Nephrol. 2012;35:238–241.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res. 2006;Suppl S1–105. DOI: 10.1291/hypres.29.S1
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI clinical practice guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis. 2015;66:884–930.
   PubMed Web of Science ®Google Scholar
• Nakai S, Masakane I, Akiba T, et al. Overview of regular dialysis treatment in Japan (as of 31, December 2005). Ther Apher Dial. 2007;11:411–441.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–1252.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Epidemiology of interdialytic ambulatory hypertension and the role of volume excess. Am J Nephrol. 2011;34:381–390.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Mallamaci F, Loutradis C, et al. Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA. Nephrol Dial Transplant. 2019;34:1542–1548.
   PubMed Web of Science ®Google Scholar
• Hypertension, by DOPPS country and cross-section. Hypertension, by DOPPS Country and Cross-Section; 2006 [cited 2016 Jul 16; 2019 Oct 30] Available from: https://www.dopps.org/annualreport/html/MCOMHTN_c_mostrec2011.htm.
   Google Scholar
• Salem MM. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis. 1995;26:461–468.
   PubMed Web of Science ®Google Scholar
• Rahman M, Dixit A, Donley V, et al. Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis. 1999;33:498–506.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Bouldin JM, Light RP, et al. Inferior vena cava diameter and left atrial diameter measure volume but not dry weight. Clin J Am Soc Nephrol. 2011;6:1066–1072.
   PubMed Web of Science ®Google Scholar
• Grekas D, Bamichas G, Bacharaki D, et al. Hypertension in chronic hemodialysis patients: current view on pathophysiology and treatment. Clin Nephrol. 2000;53:164–168.
   PubMed Web of Science ®Google Scholar
• Zager PG, Nikolic J, Brown RH, et al. “U” curve association of blood pressure and mortality in hemodialysis patients. Kidney Int. 1998;54:561–569.
   PubMed Web of Science ®Google Scholar
• Bansal N, McCulloch CE, Lin F, et al. Blood pressure and risk of cardiovascular events in patients on chronic hemodialysis: the CRIC Study (Chronic Renal Insufficiency Cohort). Hypertension. 2017;70:435–443.
   PubMed Web of Science ®Google Scholar
• Hannedouche T, Roth H, Krummel T. Multiphasic effects of blood pressure on survival in hemodialysis patients. Kidney Int. 2016;90:674–684.
   PubMed Web of Science ®Google Scholar
• Zoccali C. Arterial pressure components and cardiovascular risk in end-stage renal disease. Nephrol Dial Transplant. 2003;18:249–252.
   PubMed Web of Science ®Google Scholar
• Li Z, Lacson E Jr, Lowrie EG, et al. The epidemiology of systolic blood pressure and death risk in hemodialysis patients. Am J Kidney Dis. 2006;48:606–615.
   PubMed Web of Science ®Google Scholar
• Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA. 2002;287:1548–1555.
   PubMed Web of Science ®Google Scholar
• Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension. 2005;45:811-817.
   Google Scholar
• Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33:507–517.
   PubMed Web of Science ®Google Scholar
• Salem MM. Hypertension in the haemodialysis population: any relationship to 2-years survival? Nephrol Dial Transplant. 1999;14:125–128.
   PubMed Web of Science ®Google Scholar
• Chou JA, Streja E, Nguyen DV, et al. Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrol Dial Transplant. 2018;33:149–159.
   PubMed Web of Science ®Google Scholar
• Sands JJ, Usvyat LA, Sullivan T, et al. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. Hemodial Int. 2014;18:415–422.
   PubMed Web of Science ®Google Scholar
• Shoji T, Tsubakihara Y, Fujii M, et al. Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int. 2004;66:1212–1220.
   PubMed Web of Science ®Google Scholar
• Huang WH, Hsu CW, Hu CC, et al. Predialysis hypotension is not a predictor for mortality in long-term hemodialysis patients: insight from a single-cancer observational study. Ther Clin Risk Manag. 2016;12:1285–1292.
   PubMed Web of Science ®Google Scholar
• Robinson BM, Tong L, Zhang J, et al. Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2012;82:570–580.
   PubMed Web of Science ®Google Scholar
• Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int. 2002;62:1784–1790.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Peixoto AJ, Santos SF, et al. Pre and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure. Clin J Am Soc Nephrol. 2006;1:389–398.
   PubMed Web of Science ®Google Scholar
• Rohrscheib MR, Myers OB, Servilla KS, et al. Age-related blood pressure patterns and blood pressure variability among hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:1407–1414.
   PubMed Web of Science ®Google Scholar
• Rahman M, Griffin V, Kumar A, et al. A comparison of standardized versus ‘usual’ blood pressure measurements in hemodialysis patients. Am J Kidney Dis. 2002;39:1226–1230.
   PubMed Web of Science ®Google Scholar
• Agarwal R. Blood pressure and mortality among hemodialysis patients. Hypertension. 2010;55:762–768.
   PubMed Web of Science ®Google Scholar
• Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol. 2007;2:1228–1234.
   PubMed Web of Science ®Google Scholar
• Amar J, Vernier I, Rossignol E, et al. Nocturnal blood pressure and 24-h pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int. 2000;57:2485–2491.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Brim NJ, Mahenthiran J, et al. Out-of-hemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension. 2006;47:62–68.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Benedetto FA, Tripepi G, et al. Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. Kidney Int. 1998;53:1078–1084.
   PubMed Web of Science ®Google Scholar
• Tripepi G, Fagugli RM, Dattolo P, et al. Prognostic value of 24-h ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney Int. 2005;68:1294–1302.
   PubMed Web of Science ®Google Scholar
• O’Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–1768.
   PubMed Web of Science ®Google Scholar
• NICE. Hypertension: clinical management of primary hypertension in adults. London: NICE; 2011 [cited 2016 Nov 2]. Available from: http://guidance.nice.org.uk/CG127
   Google Scholar
• Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force blood pressure screening methods and consideration of rescreening intervals. Ann Intern Med. 2015;162:192–204.
   PubMed Web of Science ®Google Scholar
• Bansal N, McCulloch CE, Rahman M, et al. Blood pressure and risk of all-cause mortality in advanced chronic kidney disease and hemodialysis: the chronic renal insufficiency cohort study. Hypertension. 2015;65:93–100.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Peixoto AJ, Santos SF, et al. Out-of-office blood pressure monitoring in chronic kidney disease. Blood Press Monit. 2009;14:2–11.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD, Pappas MK, et al. Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial. Nephrol Dial Transplant. 2014;29:672–681.
   PubMed Web of Science ®Google Scholar
• da Silva GV, de Barros S, Abensur H, et al. Home blood pressure monitoring in blood pressure control among haemodialysis patients: an open randomized clinical trial. Nephrol Dial Transplant. 2009;24:3805–3811.
   PubMed Web of Science ®Google Scholar
• Moriya H, Oka M, Maesato K, et al. Weekly averaged blood pressure is more important than a single-point blood pressure measurement in the risk stratification of dialysis patients. Clin J Am Soc Nephrol. 2008;3:416–422.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Andersen MJ, Bishu K, et al. Home blood pressure monitoring improves the diagnosis of hypertension in hemodialysis patients. Kidney Int. 2006;69:900–906.
   PubMed Web of Science ®Google Scholar
• Moriya H, Ohtake T, Kobayashi S. Aortic stiffness, left ventricular hypertrophy and weekly averaged blood pressure (WAB) in patients on haemodialysis. Nephrol Dial Transplant. 2007;22:1198–1204.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypeertens. 2013;31:1281–1357.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;2014(311):507–520. .
   Web of Science ®Google Scholar
• Kooman JP, van der Sande F, Leunissen K, et al. Sodium balance in hemodialysis therapy. Semin Dial. 2003;16:351–355.
   PubMed Web of Science ®Google Scholar
• Krautzig S, Janssen U, Koch KM, et al. Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance hemodialysis patients. Nephrol Dial Transplant. 1998;13:552–553.
   PubMed Web of Science ®Google Scholar
• de Paula FM, Peixoto AJ, Pinto LV, et al. Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. Kidney Int. 2004;66:1232–1238.
   PubMed Web of Science ®Google Scholar
• Kayikcioglu M, Tumuklu M, Ozkahya M, et al. The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis. Nephrol Dial Transplant. 2009;24:956–962.
   PubMed Web of Science ®Google Scholar
• Weiner DE, Brunelli SM, Hunt A, et al. Improving clinical outcomes among hemodialysis patients: a proposal for a ‘volume first’ approach from the chief medical officers of US dialysis providers. Am J Kidney Dis. 2014;64:685–695.
   PubMed Web of Science ®Google Scholar
• Santos SF, Peixoto AJ. Revising the dialysate sodium prescription as a tool for better blood pressure and interdualtic weight gain management in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3:522–530.
   PubMed Web of Science ®Google Scholar
• Munoz MJ, Sun S, Chertow GM, et al. Dialysate sodium and sodium gradient in maintenance hemodialysis: a neglected sodium restriction approach? Nephrol Dial Transplant. 2011;26:1281–1287.
   PubMed Web of Science ®Google Scholar
• Munoz MJ, Bayes LY, Sun S, et al. Effect of lowering dialysate sodium concentration on interdialytic weight gain and blood pressure in patients undergoing thrice-weekly in-center nocturnal hemodialysis: a quality improvement study. Am J Kidney Dis. 2011;58:956–963.
   PubMed Web of Science ®Google Scholar
• Manlucu J, Gallo K, Heidenheim PA, et al. Lowering postdialysis plasma sodium (conductivity) to increase sodium removal in volume-expanded hemodialysis patients: A pilot study using a biofeedback software system. Am J Kidney Dis. 2010;56:69–76.
   PubMed Web of Science ®Google Scholar
• Tattersall J, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies. Nephrol Dial Transplant. 2007;22(Suppl 2):ii5–21.
   PubMedGoogle Scholar
• Rahman M, Fu P, Sehgal AR, et al. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Am J Kidney Dis. 2000;35:257–265.
   PubMed Web of Science ®Google Scholar
• Foley RN, Gilbertson DT, Murray T, et al. Long interdialytic interval and mortality among patients receiving hemodialysis. N Engl J Med. 2011;365:1099–1107.
   PubMed Web of Science ®Google Scholar
• Nitta K, Hanafusa N, Taniguchi M, et al. Annual dialysis data report 2017, JSDT Renal Data Registry. Renal Replacement Ther. 2019;5:53.
   Google Scholar
• Brunet P, Saingra Y, Leonetti F, et al. Tolerance of haemodialysis: a randomized cross-over trial of 5-h versus 4-h treatment time. Nephrol Dial Transplant. 1996;11(Suppl 8):46–51.
   PubMedGoogle Scholar
• Chan CT, Floras JS, Miller JA, et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int. 2002;61:2235–2239.
   PubMed Web of Science ®Google Scholar
• Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting “daily” hemodialysis. Kidney Int. 1999;55:2467–2476.
   PubMed Web of Science ®Google Scholar
• Kotanko P, Garg AX, Depner T, et al. Effects of frequent hemodialysis on blood pressure: results from the randomized frequent hemodialysis network trials. Hemodial Int. 2015;19:386–401.
   PubMed Web of Science ®Google Scholar
• Chertow GM, Levin NW, Beck GJ, et al. Long-term effects of frequent in-center hemodialysis. J Am Soc Nephrol. 2016;27:1830–1836.
   PubMed Web of Science ®Google Scholar
• Tandon T, Sinha AD, Agarwal R. Shorter delivered dialysis times associate with a higher and more difficult to treat blood pressure. Nephrol Dial Transplant. 2013;28:1562–1568.
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and metaanalysis of randomised controlled trials. Lancet. 2009;373:1009–1015.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis. Hypertension. 2009;53:860–866.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;2018(71):e127–e248.
   Google Scholar
• Sinda AD, Agarwal R. Clinical pharmacology of antihypertensive therapy for the treatment of hypertension in CKD. Clin J Am Soc Nephrol. 2019;14:757–764.
   PubMed Web of Science ®Google Scholar
• Abe M, Oikawa O, Okada K, et al. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. J Renin Angiotensin Aldosterone Syst. 2015;16:159–164.
   PubMed Web of Science ®Google Scholar
• Iseki K, Miyasato F, Tokuyama K, et al. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int. 1997;51:1212–1217.
   PubMed Web of Science ®Google Scholar
• Conion PJ, Walshe JJ, Heinle SK, et al. Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol. 1996;7:2658–2663.
   PubMed Web of Science ®Google Scholar
• Kooman JP, Gladziwa U, Böcker G, et al. Blood pressure during the interdialytic period in haemodialysis patients: estimation of representative blood pressure values. Nephrol Dial Transplant. 1992;7:917–923.
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Xu H, Morgenstern H, et al. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. Kidney Int. 2018;94:589–598.
   PubMed Web of Science ®Google Scholar
• Georgianos PI, Agarwal R. Pharmacotherapy of hypertension in chronic dialysis patients. Clin J Am Soc Nephrol. 2016;11:2062–2075.
   PubMed Web of Science ®Google Scholar
• Zannad F, Kessler M, Lehert P, et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 2006;70:1318–1324.
   PubMed Web of Science ®Google Scholar
• Takahashi A, Takase H, Toriyama T, et al. Candesartan, an angiotensin II type 1 receptor blocker, reduces cardiovascular events in patients on chronic hemodialysis-a randomized study. Nephrol Dial Transplant. 2006;21:2507–2512.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kanno Y, Sugahara S, et al. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis. 2008;52:501–506.
   PubMed Web of Science ®Google Scholar
• Tai DJ, Lim TW, James MT, et al. Cardiovascular effects of angiotensin converting enzyme inhibition or angiotensin receptor blockade in hemodialysis: a meta-analysis. Clin J Am Soc Nephrol. 2010;5:623–630.
   PubMed Web of Science ®Google Scholar
• Iseki K, Tokuyama K, Shiohira Y, et al. Olmesartan clinical trial in Okinawan patients under OKIDS (OCTOPUS) study: design and methods. Clin Exp Nephrol. 2009;13:145–151.
   PubMed Web of Science ®Google Scholar
• Iseki K, Arima H, Kohagura K, et al. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant. 2013;28:1579–1589.
   PubMed Web of Science ®Google Scholar
• Chan KE, Ikizler TA, Gamboa JL, et al. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int. 2011;80:978–985.
   PubMed Web of Science ®Google Scholar
• Cice G, Di Benedetto A, D’Isa S, et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. 2010;56:1701–1708.
   PubMed Web of Science ®Google Scholar
• Li SM, He QB, Chen J, et al. Combined blockade of renin-sngiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review. Atherosclerosis. 2018;269:35–41.
   PubMed Web of Science ®Google Scholar
• Preston RA, Afshartous D, Garg D, et al. Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease. Hypertension. 2009;53:754–760.
   PubMed Web of Science ®Google Scholar
• Han SW, Won YW, Yi JH, et al. No impact of hyperkalemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007;22:1150–1155.
   PubMed Web of Science ®Google Scholar
• Bushinsky DA, Rossignol P, Spiegel DM, et al. Patiromer decreases serum potassium and phosphate levels in patients on hemodialysis Am J Nephrol. 2016;44:404–410.
   PubMed Web of Science ®Google Scholar
• Rafique Z, Peacock WF, LoVecchio F, et al. Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia. Expert Opin Pharmacother. 2015;16:1727–1734.
   PubMed Web of Science ®Google Scholar
• Palmer BF. Potassium binders for hyperkalemia in chronic kidney disease-diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. Mayo Clin Proc. 2019 Oct 23;19:pii: S0025-6196. 30486-0.
   Google Scholar
• London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation. 1994;90:2786–2796.
   PubMed Web of Science ®Google Scholar
• Shibasaki Y, Masaki H, Nishiue T, et al. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron. 2002;90:256–261.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Nakamoto H, Okada H, et al. A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial. 2003;19:59–66.
   PubMedGoogle Scholar
• Kanno Y, Kaneko K, Kaneko M, et al. Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol. 2004;43:380–386.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kanno Y, Kaneko K, et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Aphel Dial. 2004;8:320–327.
   PubMed Web of Science ®Google Scholar
• Ichihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis. 2005;45:866–874.
   PubMed Web of Science ®Google Scholar
• Matsumoto N, Ishimitsu T, Okamura A, et al. Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res. 2006;29:253–260.
   PubMed Web of Science ®Google Scholar
• Yu WC, Lin YP, Lin IF, et al. Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis. 2006;47:478–484.
   PubMed Web of Science ®Google Scholar
• Leidig M, Bambauer R, Kirchertz EJ, et al. Efficacy, safety and tolerability of varsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study). Clin Nephrol. 2008;69:425–432.
   PubMed Web of Science ®Google Scholar
• Shigenaga A, Tamura K, Dejima T, et al. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis. Nephron Clin Pract. 2009;112:c31–40.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi H, Tamura K, Yamauchi J, et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis. Atherosclerosis. 2009;207:186–190.
   PubMed Web of Science ®Google Scholar
• Peters CD, Kjaergaard KD, Jensen JD, et al. No significant effect of angiotensin II receptor blockade on intermediate cardiovascular end points in hemodialysis patients. Kidney Int. 2014;86:625–637.
   PubMed Web of Science ®Google Scholar
• Peters CD, Kjaergaard KD, Jensen JD, et al. Short and long-term effects of the angiotensin II receptor blocker irbesartan on intradialytic central hemodynamics: A randomized double-blind placebo-controlled one-year intervention trial (the SAFIR Study). PLoS One. 2015;10:e0126882.
   PubMed Web of Science ®Google Scholar
• Sarafidis PA, Khosla N, Bakiris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49:12–26.
   PubMed Web of Science ®Google Scholar
• Cice G, Ferrara L, D’Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol. 2003;41:1438–1444.
   PubMed Web of Science ®Google Scholar
• Foley RN, Herzog CA, Collins AJ. United States renal data system. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS waves 3 and 4 study. Kidney Int. 2002;62:1784–1790.
   PubMed Web of Science ®Google Scholar
• Denker MG, Cohen DL. Antihypertensive medications in end-stage renal disease. Semin Dial. 2015;28:330–336.
   PubMed Web of Science ®Google Scholar
• Jadoul M, Thumma J, Fuller DS, et al. Modifiable practices associated with sudden death among hemodialysis patients in the Dialysis outcomes and practice patterns study. Clin J Am Soc Nephrol. 2012;7:765–774.
   PubMed Web of Science ®Google Scholar
• Georgianos PI, Agarwal R. Effect of lisinopril and atenolol on aortic stiffness in patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10:639–645.
   PubMed Web of Science ®Google Scholar
• Roberts MA, Pilmore HK, Ierino FL, et al. The β-blocker to lower cardiovascular dialysis events (BLOCADE) feasibility study: A randomized controlled trial. Am J Kidney Dis. 2016;67:902–911.
   PubMed Web of Science ®Google Scholar
• Weir MA, Dixon SN, Fleet JL, et al. Beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol. 2015;26:987–996.
   PubMed Web of Science ®Google Scholar
• Abe M, Soma M. Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection. Hypertens Res. 2015;38:804–806.
   PubMed Web of Science ®Google Scholar
• London GM, Marchais SJ, Guerin AP, et al. Salt and water retention and calcium blockade in uremia. Circulation. 1990;82:105–113.
   PubMed Web of Science ®Google Scholar
• Wetmore JB, Mahnken JD, Phadnis MA, et al. Relationship between calcium channel blocker class and mortality in dialysis. Pharmacoepidemiol Drug Saf. 2015;24:1249–1258.
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int. 1996;49:1379–1385.
   PubMed Web of Science ®Google Scholar
• Kestenbaum B, Gillen DL, Sherrard DJ, et al. Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 2002;61:2157–2164.
   PubMed Web of Science ®Google Scholar
• Kojima M, Taniguchi M, Sato K, et al. Antihypertensive effects of long-acting calcium channel blockers on hemodialysis days-a randomized crossover trial between benidipine and nifedipine CR. Nephron Clin Pract. 2004;97:49–53.
   PubMedGoogle Scholar
• Tepel M, Hopfenmueller W, Scholze A, et al. Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients. Nephrol Dial Transplant. 2008;23:3605–3612.
   PubMed Web of Science ®Google Scholar
• Aslam S, Santha T, Leone A, et al. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 2006;70:2109–2115.
   PubMed Web of Science ®Google Scholar
• London GM, Marchais SJ, Guerin AP, et al. Salt and water retention and calcium blockade in uremia. Circulation. 1990;82:105–113.
   PubMed Web of Science ®Google Scholar
• Yilmaz R, Altun B, Kahraman S. Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. Ren Fail. 2010;32:903–912.
   PubMed Web of Science ®Google Scholar
• Nakano N, Ishimitsu T, Takahashi T, et al. Effects of efonidipine, an L- and T-type calcium channel blocker, on the renin-angiotensin-aldosterone system in chronic hemodialysis patients. Int Heart J. 2010;51:188–192.
   PubMed Web of Science ®Google Scholar
• Ito T, Fujimoto N, Ishikawa E, et al. The effect of an L/N-type calcium channel blocker on intradialytic blood pressure in intradialytic hypertensive patients. Clin Exp Hypertens. 2019;41:92–99.
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341:709–717.
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Mori Y, Kageyama S, et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol. 2014;63:528–536.
   PubMed Web of Science ®Google Scholar
• Lin C, Zhang Q, Zhang H, et al. Long-term effects of low-dose spironolactone on chronic dialysis patients: a randomized placebocontrolled study. J Clin Hypertens (Greenwich). 2016;18:121–128.
   PubMed Web of Science ®Google Scholar
• Gross E, Rothstein M, Dombek S, et al. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis. 2005;46:94–101.
   PubMed Web of Science ®Google Scholar
• Taheri S, Mortazavi M, Shahidi S, et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl. 2009;20:392–397.
   PubMedGoogle Scholar
• Walsh M, Manns B, Garg AX, et al. The safety of eplerenone in hemodialysis patients: a noninferiority randomized controlled trial. Clin J Am Soc Nephrol. 2015;10:1602–1608.
   PubMed Web of Science ®Google Scholar
• Charytan DM, Himmelfarb J, Ikizler TA, et al. Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomize, placebo-controlled, multiple dosage trial. Kidney Int. 2019;95:973–982.
   PubMed Web of Science ®Google Scholar
• Hammer F, Malzahn U, Donhauser J, et al. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int. 2019;95:983–991.
   PubMed Web of Science ®Google Scholar
• Vukusich A, Kunstmann S, Varela C, et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1380–1387.
   PubMed Web of Science ®Google Scholar
• Taheri S, Mortazavi M, Pourmoghadas A, et al. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl. 2012;23:507–512.
   PubMedGoogle Scholar
• Ni X, Zhang J, Zhang P, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens (Greenwich). 2014;16:658–663.
   PubMed Web of Science ®Google Scholar
• Ito Y, Mizuno M, Suzuki Y, et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol. 2014;25:1094–1102.
   PubMed Web of Science ®Google Scholar
• Feniman-De-Stefano GM, Zanati-Basan SG, De Stefano LM, et al. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis. 2015;9:158–167.
   PubMedGoogle Scholar
• Yongsiri S, Thammakumpee J, Prongnamchai S, et al. Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients. Ther Apher Dial. 2015;19:81–86.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Frimat L, Zannad F. The safety of mineralocorticoid antagonists in maintenance hemodialysis patients: two steps forward. Kidney Int. 2019;95:747–749.
   PubMed Web of Science ®Google Scholar
• Tozawa M, Iseki K, Iseki C, et al. Analysis of drug prescription in chronic haemodialysis patients. Nephrol Dial Transplant. 2002;17:1819–1824.
   PubMed Web of Science ®Google Scholar
• Inrig JK. Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial. 2010;23:290–297.
   PubMed Web of Science ®Google Scholar
• Lemes HP, Araujo S, Nascimento D, et al. Use of small doses of furosemide in chronic kidney disease patients with residual renal function undergoing hemodialysis. Clin Exp Nephrol. 2011;15:554–559.
   PubMed Web of Science ®Google Scholar
• Medcalf JF, Harris KP, Walls J. Role of diuretics in the preservation of residual renal function in patients on continuous ambulatory peritoneal dialysis. Kidney Int. 2001;59:1128–1133.
   PubMed Web of Science ®Google Scholar
• van Olden RW, Guchelaar HJ, Struijk DG, et al. Acute effects of high-dose furosemide on residual renal function in CAPD patients. Perit Dial Int. 2003;23:339–347.
   PubMed Web of Science ®Google Scholar
• Bennett WM, McDonald WJ, Kuehnel E, et al. Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther. 1977;22:499–504.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Tripepi R, Torino C, et al. Ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatement of hypertension in dialysis patients. Nephrol Dial Transplant. 2015;30:1443–1448.
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Bakris G, Greene T, et al. African American study of kidney disease and hypertension study group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421–2431.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patents with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
   PubMed Web of Science ®Google Scholar
• Lopes AA, Bragg-Gresham JL, Ramirez SP, et al. Prescription of antihypertensive agents to haemodialysis patients: time trends and associations with patient characteristics, country and survival in the DOPPS. Nephrol Dial Transplant. 2009;24:2809–2816.
   PubMed Web of Science ®Google Scholar
• Karaboyas A, Xu H, Morgenstern H, et al. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients. Kidney Int. 2018;94:589–598.
   PubMed Web of Science ®Google Scholar